Inovio Pharmaceuticals (NASDAQ:INO) has been given a $13.00 price target by analysts at HC Wainwright in a research note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 189.53% from the company’s current price.

INO has been the subject of several other research reports. Citigroup initiated coverage on Inovio Pharmaceuticals in a research report on Friday, October 6th. They set a “buy” rating and a $10.00 price target for the company. BidaskClub downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. ValuEngine raised Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. Royal Bank Of Canada initiated coverage on Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They set an “outperform” rating and a $11.00 price target for the company. Finally, Zacks Investment Research downgraded Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. Inovio Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $19.16.

Inovio Pharmaceuticals (INO) opened at $4.49 on Tuesday. Inovio Pharmaceuticals has a 1 year low of $4.20 and a 1 year high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.15). The company had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The business’s quarterly revenue was down 79.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.28) EPS. sell-side analysts anticipate that Inovio Pharmaceuticals will post -1.12 EPS for the current year.

Large investors have recently made changes to their positions in the company. BlueCrest Capital Management Ltd purchased a new stake in shares of Inovio Pharmaceuticals in the second quarter valued at $107,000. Virginia Retirement Systems ET AL purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at $101,000. Neuberger Berman Group LLC purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at $115,000. Engineers Gate Manager LP purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at $117,000. Finally, Emerald Advisers Inc. PA grew its position in shares of Inovio Pharmaceuticals by 84.0% in the third quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock valued at $129,000 after purchasing an additional 9,280 shares during the period. 32.29% of the stock is owned by institutional investors and hedge funds.

WARNING: “Inovio Pharmaceuticals (INO) PT Set at $13.00 by HC Wainwright” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/inovio-pharmaceuticals-ino-pt-set-at-13-00-by-hc-wainwright/1734455.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.